Global Pharmaceutical Intermediates Market - 2020-2027
|医药品中间体的全球市场 (2020年～2027年) Global Pharmaceutical Intermediates Market - 2020-2027|
|出版日期: 2020年11月04日||内容资讯: 英文||
The global pharmaceutical intermediates market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Pharmaceutical intermediates are the synthetic aggravates that are the building squares utilized in the generation of dynamic pharmaceutical fixings. Pharmaceutical intermediates are created amid the way toward assembling or amalgamation of dynamic pharmaceutical fixings. These pharmaceutical intermediates additionally experience sub-atomic changes and preparing before turning into a functioning pharmaceutical fixing.
The global pharmaceutical intermediates market growth is driven by the increasing use of pharmaceutical intermediates in the fundamental base part of active pharmaceutical ingredients (APIs), the market is also expected to witness upsurge in demand in forecast period.
Increasing Prevalence of Chronic Diseases is expected to drive the growth in the forecast period
The rapidly increasing prevalence of chronic diseases and the growth of the aging population across the world are among factors that are expected to increase the need for drug formulations for the management of chronic diseases. For example, according to the World Health Organization (WHO), the prevalence of diabetes has surged from 108.0 million in 1980 to 422.0 million in 2014, and the number is rising rapidly.
Furthermore, according to the World Health Organization (WHO), the prevalence of chronic diseases is expected to increase by 57.0% by 2020, which indicates that a significant percentage of population is suffering from chronic diseases. These factors are driving the growth of the market in the forecast period.
Increasing investments in manufacturing expected to drive the market growth
Leading pharmaceutical companies in pharmaceutical intermediates market have announced their intentions to invest in manufacturing facilities due to various reasons such as to enhance the production capacity of pharmaceutical intermediates, reduce corporate tax rate and to increase their global footprints as well as their presence in emerging markets.
For instance, in July 2018, Pfizer invest around US$ 465.0 million to build a sterile injectable plant in Portage, Michigan. This step is a part of its announcement that it had made earlier in 2018 about its plans to invest around US$ 5.0 billion in a U.S.-based capital project due to the recent corporate tax reforms in the country. These factors are driving the growth of the market in forecast period.
Regulatory obstruction is likely to hinder the market growth
On the contrary, rising monetary pressure as well as regulatory obstruction is expected to freeze the growth of pharmaceutical intermediates market in the forecast period.
COVID-19 Impact Analysis
The disruptive effects of the coronavirus COVID-19 have placed enormous strain on the global supply of pharmaceutical intermediates, increasing the risk of shortages. Although production across various industries and regions in China has been gradually resuming since late February, U.S. pharmaceutical intermediates manufacturers, which heavily source directly and indirectly from China, are now exposed to high risks in supply shortages over the next one to two months. These risks are due primarily to limited operational capacity in China and how resumption of production will be prioritized. Thesse factors are restraning the growth of the market in the forecast period.
By application the pharmaceutical intermediates market is classified into analgesics, anti-infective drugs, cardiovascular drugs, oral antidiabetic drugs, antimicrobial drugs, others.
Cardiovascular drugs segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Cardiovascular diseases are the leading cause of deaths worldwide. According to the American College of Cardiology, cardiovascular disease (CVD) accounted for 800,000 deaths in the United States in 2017 alone. Among Americans, an average of one person dies from cardiovascular disease, every 40 seconds. Coronary heart disease (CHD) accounts for the majority of CVD deaths, followed by stroke and heart failure. According to the European Heart Network, every year, cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).
This high prevalence of cardiovascular diseases is generating a huge demand for cardiovascular drugs, which, in turn, is expected to propel the growth in the need for various pharmaceutical intermediates. Hence, owing to the aforementioned factors, the concerned segment of the pharmaceutical intermediates market is expected to observe steady growth over the forecast period.
Analgesics segment has the positive market growth in the forecast period. Analgesics, or painkillers, are used to reduce and treat aches and pains. Internal and external analgesics are used to combat pain resulting from inflammation, cancer treatments, physiological injury, neuropathic conditions, surgeries, wounds, and phantom aches. The most prominent therapeutic classes of analgesics are local anesthesia, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. The growing incidence of cancer worldwide and the rise in chronic diseases are mainly responsible for the consistent growth of the global analgesics market. In 2017, between 950-1000 million people were over the age of 60. However, by 2050, these numbers are expected to reach 2100 million, accounting for around 21% of the total global population. As older adults are more vulnerable to chronic and lifestyles diseases, it will significantly contribute to the sales of analgesics. Apart from this, many leading pharmaceutical companies are continually focusing on clinical advancements in both the delivery and design of analgesic drugs. They are also developing safer opioids with improved side effect profiles and effective pain relief. Moreover, the presence of a strong drug pipeline with efficacious drugs waiting for approvals by the United States Food and Drug Administration (USFDA) is further expected to enhance the use of analgesics across the globe.
North America region holds the largest market share global Pharmaceutical Intermediates
North America region is dominating the global Pharmaceutical Intermediates accounted for the largest market share in 2019, due to the advanced research and development facilities mainly across the United States and Canada. In addition, the rising prevalence of various chronic conditions is also fueling market growth across the region. The U.S. holds the largest market for H1N1 vaccination, followed by Canada, in North America. For instance, in December 2019, NACI (National Advisory Committee on Immunization) published scientific information and recommendation on MenB-fHBP (bivalent factor-H binding protein meningococcal serogroup B) vaccine (Trumenba). The presence of a strong pipeline of meningococcal vaccines is expected to maintain a significant market share of the region.
According to the 2017 report of Health Library, Cardiovascular disease, listed as the underlying cause of death, accounts for nearly 801,000 deaths in the US. That is about 1 of every 3 deaths in the US. About 2,200 Americans die of cardiovascular disease each day, an average of 1 death every 40 seconds.
However, the Asia-Pacific market is anticipated to witness the highest growth during the forecast period, due to increasing healthcare expenditure. Additionally, the low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to the Asia-Pacific region from across the world.
The Pharmaceutical Intermediates is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Aceto Corporation, BASF SE, Chiracon GmbH, Yin-sheng Bio-tech Co., Ltd., Dishman Group, Green Vision Life Sciences, Midas Pharma GmbH, Sanofi SA, Vertellus Holdings LLC., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Pharmaceutical Intermediates globally.
Overview: Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Specialty Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.
Product Portfolio: The Company's portfolio comprised of drugs, generic medicines, food supplement, cosmetics, and medical devices such as cancer, cardiology, gynecology, and diabetes.
The global pharmaceutical intermediates market report would provide an access to an approx. 62 market data table, 60 figures and 300 pages.
LIST NOT EXHAUSTIVE